DRL Acquires Haleon’s Global NRT Portfolio

Hyderabad: Dr Reddy’s Laboratories (DRL) on Monday said its Switzerland-based subsidiary has completed the acquisition of Haleon plc’s global portfolio of consumer healthcare brands, outside of the US, in the Nicotine Replacement Therapy (NRT) category, through the purchase of shares of Northstar Switzerland SARL, a Haleon group company.

“We would like to inform you that acquisition has now been completed, and the Company has made payment of upfront cash consideration of GBP 458 million. As part of this acquisition, Northstar Switzerland along with its wholly-owned subsidiaries, North Star OpCo Ltd (United Kingdom) and North Star Sweden AB (Sweden) are now wholly-owned step-down subsidiaries of the Company with effect from September 30, 2024,” the Hyderabad-based drug major said in a regulatory filing.